Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (HK:1801)
:1801
1801 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$28.65 - HK$52.15
Previous CloseN/A
Volume9.75M
Average Volume (3M)16.36M
Market Cap
$75.68B
Enterprise ValueHK$54.07B
Total Cash (Recent Filing)¥7.66B
Total Debt (Recent Filing)¥3.43B
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 27, 2025EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,638,187,500
10 Day Avg. Volume19,428,359
30 Day Avg. Volume16,358,466
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$52.43Price Target Upside13.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Innovent Biologics News
PremiumCompany Announcements
Innovent Biologics Grants Share Options to Key Personnel
PremiumCompany Announcements
Innovent Biologics Reports Strong 2024 Financial Results
PremiumCompany Announcements
Innovent Biologics Achieves Historic Financial Milestone in 2024
PremiumCompany Announcements
Innovent Biologics Schedules Board Meeting to Approve Annual Results
---
Bulls Say, Bears Say
Bulls Say
Drug PipelineInnovent Biologics possesses a rich innovative drug pipeline with global potential, including multiple ADC assets and next-generation IO assets demonstrating encouraging results.
Product ApprovalsInnovent announced it had received marketing approval from the National Medical Products Administration for its next-generation ROS1 tyrosine kinase inhibitor, DOVBLERON, for the treatment of patients with 2L ROS1+ non-small cell lung cancer.
Strategic PartnershipsInnovent Biologics has out-licensed the global rights of a novel DLL3 ADC to Roche through a blockbuster deal, receiving an upfront payment and potential milestone payments, along with tiered royalties on net sales.
Bears Say
Commercial PerformanceThe ROS1 mutation constitutes 2-3% of all Chinese NSCLC patients, representing a substantial commercial opportunity for Innovent.
Corporate GovernanceInnovent demonstrates respect for investor opinions by cancelling a related-party transaction, highlighting strong corporate governance.
Market CompetitionDLL3-targeted therapy has become increasingly dynamic with significant transactions, highlighting the strategic value of Innovent Biologics' partnerships and assets.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
10.13%
Mutual Funds
― Other Institutional Investors
82.39% Public Companies and
Individual Investors
1801 FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$28.65 and its highest was HK$52.15 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is $75.68B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Aug 27, 2025 which is in 149 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Mar 26, 2025. The company reported HK$0.196 earnings per share for the quarter, beating the consensus estimate of -HK$0.25 by HK$0.445.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.24.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,638,187,500 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of HK$0.196 in its last earnings report, beating expectations of -HK$0.25. Following the earnings report the stock price went down -0.255%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
---
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$52.43 (13.48% Upside)
HK$52.43 (13.48% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.49%
12-Months-Change
Fundamentals
Return on Equity
-0.72%
Trailing 12-Months
Asset Growth
1.76%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
---
1801 Stock 12 Month Forecast
Average Price Target
HK$52.43
▲(13.48% Upside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Livzon Pharmaceutical Group
―
Wuxi Biologics (Cayman)
―
Best Analysts Covering 1801
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+12.26%
reiterated a buy rating 3 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +12.26% per trade.
---